Market Overview

Cowen Suspends PTC Therapeutics Target, Puts Rating Under Review

Related PTCT
The Market In 5 Minutes: Low Floats, Ron Johnson, And Jobless Claims
30 Stocks Moving In Thursday's Pre-Market Session

Cowen’s Ritu Baral put the prior Outperform rating for PTC Therapeutics, Inc. (NASDAQ: PTCT) under review, while suspending the previous $120 price target, after the company announced it had not been able to agree with German reimbursement authorities on price and may have to withdraw the Translarna™ [Ataluren] drug from the German market.

Currently, Germany is the only region in which the drug has been commercially launched. The recent development creates significant uncertainly around the EU commercial opportunity, analyst Ritu Baral said.

Related Link: Sanofi In Talks To Buy PTC Therapeutics

She wrote further, “This jeopardizes our entire EU valuation of Translarna, given Germany’s position as the largest market in the EU as well as the process of reference pricing, which normally suggests that prices in Germany are among the highest in Europe.”

PTC Therapeutics has also received a refuse-to-file from the FDA on its Translarna DMD NDA. “We do not think that the agency rejection of the application was for benign or administrative reasons…As a result, our valuation of Translarna in the US is also in question,” Baral mentioned.

Latest Ratings for PTCT

Feb 2018CitigroupMaintainsBuyBuy
Nov 2017JP MorganUpgradesUnderweightNeutral
Oct 2017Bank of AmericaDowngradesNeutralUnderperform

View More Analyst Ratings for PTCT
View the Latest Analyst Ratings

Posted-In: Cowen Ritu BaralAnalyst Color Health Care Analyst Ratings General


Related Articles (PTCT)

View Comments and Join the Discussion!